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Sulphonylureas are widely used in the treatment of Diabetes mellitus, one of the main causes of death in human population. Their 
determination is essential in pharmacological research and in the development of new drugs. Generally, determination of 
sulphonylureas in biological matrices is performed using conventional sample preparation techniques, which frequently leads to 
an increase of analysis time and errors. In this context, a bioanalytical method for the simultaneous determination of 
sulphonylureas by direct injection of human plasma was developed and optimized. An automated column-switching high 
performance liquid chromatographic system with a restricted access media (RAM) column coupled to a fused-core column was 
employed. At the first dimension, a RAM column with mobile phase of ultrapure water pH 6.0 at a flow-rate of 1.0 mL min-1 was 
used. The valve switching time was 3 minutes. At the second dimension, a C18 guard-column coupled to a C18 fused core column 
with mobile phase of acetonitrile and 10 mM phosphate buffer pH 3.0 (54:46 v/v) at a flow-rate of 0.8 mL min-1 were employed. 
The column switching system was performed in backflush configuration with an analyte elution time of 1 minute. Flufenamic acid 
was used as the internal standard. The mean plasma protein exclusion percentage by the RAM-column was 104.5%. The 
developed and optimized method showed to be fast and simple, allowing the direct injection of biological sample into the 
chromatographic system and the simultaneous determination of three sulphonylureas in only 12 minutes, including the sample 
treatment, separation and detection. 
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Introduction  
 
The analysis of drugs and metabolites in biological samples, 
mainly in plasma, is a common procedure for clinical 
diagnoses, toxicological analysis and pharmacological 
research. Recurrent problems found in bioanalysis are 
analytes low concentration, interferences due to the presence 
of other compounds and plasma proteins, and analyte-
protein binding (1,2). 
When high-performance liquid chromatography (HPLC) is 
used for the analysis of biological matrices, a pre-treatment 
is necessary before the injection of the sample in the system. 
This procedure aims to concentrate the analyte and eliminate 
plasma proteins, since these macromolecules may suffer 
irreversible adsorption in the stationary phase of the 
analytical column, shortening its lifetime and increasing the 
system pressure. Therefore, the sample preparation is a 
critical and limiting step in the development of analytical 
methods for the determination of drugs in biological fluids 
by HPLC (1,3-5). 
The sample preparation techniques may be classified in 
conventional and modern. Modern or miniaturized 
techniques are characterized by reduced analysis time and 
organic solvent consumption, as well as automation. Among 
the modern sample preparation techniques, online solid 
phase extraction (SPE) using restricted access media 
columns (RAM) deserve attention. This kind of support 
allows the direct injection of biological samples in the 
chromatographic system, because of its macromolecules 
exclusion mechanism, restraining their access to the 
support’s adsorption sites (6,7). 
The direct injection of biological samples in the 
chromatographic system, through online mode, allows the  
 
reduction of the sample handling by the analyst, who will be 
less exposed to the sample and to toxic compounds. Also, 
the sample will be subject to less oxidation and evaporation, 
and the occurrence of error during the analysis will be 
lower. The automated mode employing RAM columns can 
be performed using a two-dimensional chromatographic 
system, controlled by a valve, with the extraction phase in 
the first dimension and the analytical step in the second 
dimension. First, the biological sample, usually plasma, is 
injected into the first dimension of the system and carried to 
the RAM column by the exclusion mobile phase (EMP), 
with the valve at position A. In the RAM column, the 
analytes are retained in the stationary phase and plasma 
protein excluded and discarded. After that, the automatic 
valve rotates to position B, and the analytical mobile phase 
(AMP) runs through the RAM column eluting the analytes 
into the analytical column, where separation occurs (Figure 
1). In the backflush configuration, the AMP runs through the 
RAM column in an opposite flow direction of the EMP. 
Oppositely, in the foreflush configuration both AMP and 
EMP runs in the same direction through the RAM column 
(2,5,6,8-11). 
Diabetes mellitus (DM) is one of the main causes of death in 
human population. It is estimated that DM affects the lives 
of about 382 millions of people in the world. It can be 
classified in type 1 – autoimmune disease in which a 
catabolic disturb leads to the absence of insulin, and type 2 – 
heterogenic pathology encompassing many forms of 
diabetes, which have in common the insulin insufficiency or 
tissue insensitivity. Its treatment involves lifestyle change, 
maintenance of ideal weight and use of oral antidiabetic 
drugs, such as sulfonylureas. Figure 2 shows the chemical 
structure and some physical-chemical properties of the 
sulfonylureas analyzed in this study. These drugs are 
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completely and rapidly absorbed by the gastrointestinal tract 
and are bound to plasma proteins, mainly albumin, by about 
90-99%. They are metabolized in the liver and their 
metabolites are excreted in urine (12-15). 
 
 
Figure 1. Backflush and foreflush configurations for the two-
dimensional chromatographic system. 
 
 
 
Figure 2. Chemical structures of the analyzed sulfonylureas (GB, 
GM and GZ) and the internal standard (AF). 
Sulphonylurea determination in biological fluids is 
commonly performed employing conventional sample 
preparation techniques. When modern techniques are used 
they are not automated. In a review of the recent literature 
on the quantification of sulfonylureas in biological samples 
using HPLC, the majority of the studies refers to the use of 
protein precipitation (PP) (16-18) or liquid-liquid extraction 
(LLE) (19-21). Lately, modern approaches have been 
described, such as dispersive SPE with magnetic material 
(22) and microextraction by packed sorbent (23). Despite of 
presenting some advantages over conventional techniques, 
their main limitation is the lack of automation. One study 
was found describing the determination of glimepiride (GM) 
in plasma using column-switching with RAM column. The 
total time spent to determine only one sulfonylurea was 40 
minutes (24). 
In this context, the present study describes the optimization 
of a rapid and simple method, using a column-switching 
HPLC with RAM column (sample preparation) and fused 
core column (analytical separation), for the simultaneous 
determination of three sulfonylureas: glibenclamide (GB), 
GM and gliclazide (GZ), in human plasma. 
 
Experimental 
Chemicals and reagents 
GB active pharmaceutical ingredient (API), 99.50% of 
purity, from Cadila Pharmaceuticals (Ahmedabad, Gujarat, 
India) was donated by Fundação Ezequiel Dias – FUNED 
(Belo Horizonte, Brazil). GZ API, 99.10% of purity, from 
Shandong Keyuas Pharmaceutical (Jinan, Shandong, China) 
and GM API, 99.96% of purity, from Mantena Laboratories 
(Naldonga, Dist, Andhra Pradesh, India) were donated by 
Cifarma (Belo Horizonte, Brazil). Flufenamic acid (FA), 
used as internal standard, was from Sigma-Aldrich 
(Steinheim, Germany) (Figure 2). Acetonitrile Panreac 
(Barcelona, Spain) and methanol Sigma-Aldrich (Steinheim, 
Germany) were of HPLC grade. Other analytical solvents 
and reagents were: acetic acid and monobasic potassium 
phosphate Sigma-Aldrich (Steinheim, Germany), ortho-
phosporic acid Merck (Darmstadt, Germany) and sodium 
hydroxide Quimex (São Paulo, Brazil). 
 
Equipment and materials 
    
Chromatography was performed in a Shimadzu (Kyoto, 
Japan) system composed by a SCL-10A VP controller, two 
LC-10AD VP pumps, a CTO-10A VP oven, a SIL-10AD 
VP automated injector, a SPD-M10A VP diode array 
detector (DAD), and a Cheminert six port valve (VICI - 
Brockville, Canada). A Poroshell 120 EC-C18 (100 x 4.6 
mm, 2.7 μm) fused core column from Agilent Technologies 
(Santa Clara, USA) and a C18 pre-column (4.0 mm x 3.0 
mm) from Phenomenex (Torrance, USA) were used for 
separation. Extraction was performed in a RAM Merck 
Lichrospher C18 ADS (25 x 4.0 mm, 25 μm) column 
(Darmstadt, Germany). 
 
 
 
Biological sample 
 
The human plasma samples, obtained by donation from 
healthy volunteers, were collected in the Laboratório de 
Hematologia Clínica from Faculty of Pharmacy - Federal 
University of Minas Gerais. The study was approved by the 
ethical committee (CAAE number 01892012.0.0000.5149). 
The blood collection was performed in the morning, with the 
volunteers fasted or having a light breakfast, characterized 
by low calorie food and without coffee and chocolate. 
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Heparin tubes were used for collection. The blood samples 
were centrifuged at 480 x g for 10 minutes at 4 °C and the 
obtained supernatant (plasma) was separated and stored at -
70 °C until its use. 
 
Preparation of chemicals solutions 
Stock solutions of GB, GM and GZ at 0.5 mg mL-1 in a 
mixture of acetonitrile and water 4:1 (v/v) were individually 
prepared. Work solutions were prepared diluting 1 mL of 
each stock solution in acetonitrile and water 50:50 (v/v). The 
final concentration was 100 µg mL-1. Internal standard work 
solution was prepared at 0.1 mg mL-1 in methanol.. 
 
Spiked plasma samples 
 
              After thawing, the plasma samples were centrifuged at 
10410 x g for five minutes, spiked with the work solutions 
and, then, vortexed for 30 seconds in 2200 rpm. The final 
concentration was 5 µg mL-1. 
 
Evaluation of protein exclusion by RAM-ADS column 
 
           First, different volumes of blank human plasma (20, 50, 100, 
200 and 500 µL) were injected in a chromatographic system 
without the analytical and RAM columns. Water as mobile 
phase at 1 mL min-1 and UV detection at 280 nm were used. 
Afterwards, the RAM-ADS column was added to the 
chromatographic system, still without the analytical column, 
and the same volumes of blank human plasma were injected. 
By comparing the peak´s areas from the two configurations 
described above, the protein exclusion percentage of the 
RAM column for the tested volumes was established. 
 
Optimization of instrumental parameters and 
chromatographic conditions 
 
        First, the UV-visible spectra (from 190 to 800 nm) of the 
sulfonylureas and of the internal standard at 0.1 mg mL-1 
were obtained. Next, the time needed to EMP exclude the 
proteins from plasma samples was established by analyzing 
the chromatograms obtained during the evaluation of the 
protein exclusion by the RAM-ADS column. At this 
moment, the valve was at position A. After complete 
exclusion of plasma proteins, the valve was switched to 
position B, when the AMP ran through the RAM-ADS 
column eluting the retained analytes. The influence of the 
valve position (maintaining in the position B or returning to 
position A) in the peak area was evaluated. In the case of 
returning to position A, different switching times (30, 60, 90 
and 120 seconds) were tested. 
Ultrapure water in different pH values (4.0, 5.0, 6.0 and 7.0) 
was tested as EMP. Different compositions of the AMP 
were tested, using acetonitrile as organic phase and acetic 
acid 1% or 10 mM potassium phosphate buffer as aqueous 
phase, both with pH 3.0). Also, different proportions and 
flow-rates were evaluated, as long as the elution mode: 
isocratic or gradient. After that, different sample volumes 
(20, 50, 100, 200 and 500 µL) were injected, in order to 
evaluate the effect on the method detectability. 
In order to establish the more appropriate column-switching 
configuration for the simultaneous analysis of the three 
sulfonlyureas, backflush and foreflush were assessed (Figure 
1).  
 
Protein precipitation 
 
     The effect of a previous PP on the analyte’s peak area was 
tested. The analyte’s peak area obtained with PP, RAM-
ADS, both alone, and with the combination of RAM and PP 
were compared. For PP, acetonitrile was added to the spiked 
plasma in the proportion of 1:1 (v/v) (25) followed by vortex 
for 1 minute and centrifugation at 10410 x g during 5 
minutes. Then, the supernatant was collected and filtered in 
regenerated cellulose membrane filter (0.45 μm). 
  
Results and discussion 
 
Evaluation of protein exclusion by RAM-ADS column 
 
After the analysis of blank plasma samples using the 
chromatographic system without (representing the 
concentration of 100% of plasma proteins), and with 
(representing plasma proteins excluded) the RAM-ADS 
column, plasma protein exclusion percentage by RAM-ADS 
column, for each volume injected, was calculated (Table 1). 
The values obtained were considered satisfactory, since it 
was higher than 100% for all tested volumes. The mean was 
104.5%, with a relative standard deviation of only 2.15%, 
indicating total exclusion of plasma proteins by the RAM-
ADS column in less than 2 minutes (Figure 3).  
 
 
Table 1 – Plasma protein exclusion percentages by the RAM-ADS 
column. 
Injection volume 
(µL) 
                   Peak area 
Exclusion 
(%) Without 
RAM With RAM 
20 20509651 20674455 100.8 
50 32340063 34123606 105.5 
100 45236230 48327986 106.8 
200 49928515 52410799 104.9 
500 50935121 53198585 104.4 
Mean 104.5% 
RSD 2.15 
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Figure 3. Chromatograms obtained before and after plasma protein 
exclusion by the RAM-ADS column. Sample volume: 200 L. 
Mobile phase: ultrapure water, flow-rate: 1.0 mL min-1. Wavelength 
detection: 280 nm.  
 
 
Optimization of instrumental parameters and 
chromatographic conditions 
           In order to choose the internal standard for the bioanalytical 
method, different compounds available in our study group, 
with similar physical-chemical properties, retention time and 
maximum absorption wavelengths as the sulfonylureas, 
were evaluated. Considering these requirements, FA (logP 
of 5.25 and pKa of 3.88) was chosen as the internal 
standard. A maximum absorption at 230 nm was observed 
for the sulfonylureas and FA, when solutions at 0.1 mg mL-1 
in methanol were tested from 190 to 800 nm. Therefore, 230 
nm was chosen for the chromatographic method. 
As can be observed in Figure 3, after 3 minutes 100% of 
plasma proteins were excluded from the RAM-ADS column 
for all volumes tested. Therefore, at 3 minutes after injection 
the valve was switched from position A to position B. 
The chromatograms of blank and spiked plasma, without 
returning the valve to the initial position (position A) are 
presented in Figure 4. The interference of the blank plasma 
in the peaks of the analytes makes their integration 
inappropriate. Thus, the returning of the valve from position 
B to position A was necessary. Different time intervals (30, 
60, 90 and 120 seconds) were tested. At 90 and 120 seconds, 
the determination of GZ peak area was not possible due to a 
co-elution with a plasma interference. Therefore, 60 seconds 
was selected, since there was an increase in the peak area for 
all the analytes and the internal standard when compared to 
30 seconds (Figure 5)  
Ultrapure water, a weak solvent in reversed phase, was used 
as EMP because of its low affinity for the analytes and IS, 
assuring a high interaction of these analytes with the RAM-
ADS column. Besides that, water has the ability to ionize the 
sample proteins favoring their exclusion by electrostatic 
repulsion inside the RAM-ADS column. Aiming to evaluate 
the elimination of the proteins, four values of pH were 
evaluated: 4.0, 5.0, 6.0 and 7.0. When neutral pH was used, 
a lack of resolution between the chromatographic peaks was 
observed. At pH 4.0, a residual effect related to the IS was 
observed in the chromatogram of blank plasma obtained 
after the analysis of spiked plasma. Since this phenomenon 
was not observed in pH 5.0 and 6.0, this range was 
employed. 
 
 
Figure 4. Chromatograms obtained for the analysis of spiked and 
blank plasma, without returning the valve from position B to A. 
Sample volume: 200 L. EMP: ultrapure water, flow-rate: 1.0 mL 
min-1. AMP: acetonitrile and 10 mM phosphate buffer pH 3.0 
(54:46 v/v), flow-rate: 0.8 mL min-1. Wavelength detection: 230 
nm. 
 
 
Figure 5. Peak areas of GB, GM, GZ and IS in different time 
intervals, after which the valve was switched from position B to 
position A. 
Different AMP compositions were tested using acetonitrile 
(organic phase) and acetic acid 1% or 10 mM phosphate 
buffer, both at pH 3.0 (aqueous phase), varying the 
proportion of the phases, flow-rate and elution mode 
(gradient or isocratic). In view of the obtained results in 
terms of resolution and baseline noise, AMP was composed 
by acetonitrile and 10 mM phosphate buffer pH 3.0, in 
isocratic mode (54:46 v/v), in a flow-rate of 0.8 mL min-1. 
Different sample volumes of human plasma were evaluated. 
As can be observed in Table 2, there was an improvement in 
the chromatographic peak areas and heights when the 
injection volumes were increased. An exception was a 
decreasing in peak areas and heights when the volume 
changed from 200 to 500 µL of plasma. A possible reason is 
the saturation of the RAM column, reducing its capacity to 
adsorb the analytes. Due to the decrease in peak area and 
height when 500 µL of the sample was injected in the 
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chromatographic system, 200 µL was defined as the 
injection volume, since there was an increase in the peaks 
when compared to the injection of 100 µL of plasma, 
improving the method detectability. It is important to note 
that during this step of the method development, blank 
plasma samples were injected between spiked samples 
analysis and no carry-over effect was observed. 
 
Table 2 – Variation of peaks areas and heights as a function of the volume of injected plasma(µL). 
  
20 → 50 (%) 50 → 100 (%) 100 → 200 (%) 200 → 500 (%) 
Area 
GZ 133.1      95.9      18.1 - 3.8 
GB 89.4      226.0      7.3 - 5.5 
GM 200.1      313.1      4.4 - 8.4 
IS 88.0      173.3      2.8 - 2.6 
Mean 127.6      202.1      8.2 - 5.1 
Height 
GZ 133.5      96.2      7.1 - 2.9 
GB 116.6      232.2      3.6 - 4.9 
GM 228.2      315.5      2.9 - 8.3 
IS 137.6      197.3      2.8 - 2.2 
Mean 154.0      210.3      4.1 - 4.6 
 
After the optimization of the chromatographic conditions, 
backflush and foreflush modes were compared for the 
simultaneous determination of GB, GM and GZ. In foreflush 
configuration a baseline noise was observed, which 
compromised the appropriate peak integration. Moreover, 
the resolution between the sulfonylureas was poor. A 
possible reason is the flow direction of the AMP, which is 
the same of the EMP. Therefore, the analytes eluted through 
the whole length of the RAM column before achieve the 
analytical column. This might lead to the adsorption of the 
analytes along the RAM column, resulting in peak 
broadening. 
On the other hand, in backflush mode, the flow direction of 
the AMP is opposite to the EMP. Therefore, the analytes 
adsorbed in the head of the RAM column were eluted 
directly into the analytical column, going through a small 
pathway resulting in less extra column volume and avoiding 
peak broadening. In view of the obtained results and the 
small amount of time spent in the analysis of the studied 
sulfonylureas, only 12 minutes, backflush was the selected 
column-switching configuration. 
 
Protein precipitation 
 
When PP was used as a single technique, the peak area for 
all analytes increased with higher injected plasma volumes. 
This gain was much more pronounced when the volume was 
100 µL (Figure 6). Possibly, the increase would be higher 
with 200 and 500 µL; however, it was not possible to 
identify the compound’s peaks due to baseline noise and 
poor resolution between the analytes. As can be observed, 
the peak areas were higher for PP when compared with 
RAM-ADS and RAM-ADS + PP. A possible reason is the 
disruption of drug-protein binding by the organic solvent, 
improving analytes recovery. 
Despite the higher peak areas observed with PP, it was not 
considered for the analysis of the studied sulfonylureas, in  
 
 
 
 
view of the increased analysis time, chance of errors, and 
analyst exposure, since it is a non-automated technique.         
The peak areas obtained with RAM-ADS column were 
similar to those obtained with the combination of both 
techniques (PP + RAM), another indication of a possible 
saturation of the RAM column. Therefore, the RAM column 
was maintained as the only sample treatment technique, 
since its combination with PP did not add any improvement. 
Figure 7 shows the chromatogram of blank and spiked 
plasma samples obtained with the optimized method. 
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Figure 6. Peak areas of GB, GM, GZ and IS as a function of the sample treatment technique and of the volume of injected plasma (µL). 
 
 
                                         
 
Figure 7. Chromatograms obtained after the injection of spiked 
plasma followed by blank plasma using the optimized method. 
Sample volume: 200 μL. EMP: ultrapure water, pH: 6.0; flow: 1.0 
mL min-1. AMP: acetonitrile and phosphate buffer 10 mM pH 3.0 
(54:46), flow: 0.8 mL min-1. Wavelength: 230 nm. 
 
Conclusion 
 
The column-switching system using the backflush 
configuration, which employed a six-port valve, allowed the 
use of two dimensions in the chromatographic system, one 
for sample treatment and the other for separation. This 
system allowed the direct injection of human plasma 
samples in the chromatographic system. 
The developed method showed several advantages over 
those already published in the peer-review literature dealing 
with sulphonylureas determination: less exposure of the 
analyst to the biological sample and to the solvents used in 
the analysis, less chances of errors due to the handling of the 
samples and reduction of the time spent in the analysis, 
increasing the productivity and reducing the expense of 
organic solvents.  
The developed method demonstrated to be simple and fast, 
in addition to allowing simultaneous determination of three 
sulfonylureas, glibenclamide, glimepiride and gliclazide, in 
human plasma. The total analysis time, encompassing the 
chromatographic step (8 minutes) and the sample treatment 
step (3 minutes for the protein exclusion and 1 minute for 
the analytes elution) was only 12 minutes.  
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